Salem Capital Management’s GSK GSK Stock Holding History

Salem Capital Management’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-4,680	Closed	-$252K	–	66
2016 Q3	$252K	Hold	4,680	–	–	0.14%	60
2016 Q2	$254K	Sell	4,680 -79,988	-94%	-$4.21M	0.15%	60
2016 Q1	$4.29M	Sell	84,668 -3,288	-4%	-$164K	2.41%	18
2015 Q4	$4.44M	Buy	87,956 +676	+0.8%	+$34.5K	2.51%	17
2015 Q3	$4.2M	Sell	87,280 -1,496	-2%	-$77.9K	2.46%	18
2015 Q2	$4.62M	Sell	88,776 -1,960	-2%	-$110K	2.4%	20
2015 Q1	$5.23M	Sell	90,736 -1,280	-1%	-$73.4K	2.66%	18
2014 Q4	$4.92M	Sell	92,016 -4,400	-5%	-$246K	2.34%	20
2014 Q3	$5.54M	Buy	96,416 +4,912	+5%	+$301K	2.58%	19
2014 Q2	$6.12M	Sell	91,504 -3,036	-3%	-$205K	2.71%	17
2014 Q1	$6.31M	Sell	94,540 -2,320	-2%	-$157K	2.77%	16
2013 Q4	$6.46M	Buy	96,860 +160	+0.2%	+$10.4K	2.79%	13
2013 Q3	$6.06M	Sell	96,700 -1,320	-1%	-$85K	2.79%	13
2013 Q2	$6.12M	Buy	+98,020	New	+$6.22M	2.92%	9

Other funds holding GSK

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

Hotchkis & Wiley Capital Management Los Angeles, California $34.3B AUM 22.63% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Salem Capital Management's GSK Position: Q4 2016 in Review

Salem Capital Management sold out of GSK (GSK) in Q4 2016, closing a stake of 4,680 shares — an estimated $252K sold.

Salem Capital Management first reported a position in GSK in Q2 2013 and held it in 14 quarters. The position peaked at $6.46M in Q4 2013. 763 funds tracked by Wall St. Rank hold GSK as of Q4 2016.

Salem Capital Management reported no remaining GSK position as of Q4 2016 after selling out during the quarter.
Salem Capital Management sold 4,680 GSK shares in Q4 2016, an estimated $252K.
Salem Capital Management first reported a position in GSK in Q2 2013 and held it in 14 quarters.
Salem Capital Management's GSK position peaked at $6.46M in Q4 2013.
763 funds tracked by Wall St. Rank held GSK as of Q4 2016.

Based on Salem Capital Management's 13F filing for Q4 2016, filed 9 Jan 2017.